Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been clinically diagnosed with cutaneous T-cell lymphoma or peripheral T-cell lymphoma that affects the skin, confirmed by a laboratory examination of skin tissue samples.
• People who have measurable areas of skin disease, as assessed using a specific skin scoring tool called the mSWAT (including skin lesions in previously treated areas, if those lesions have continued to grow).
• People who have at least two skin lesions that are large enough and in a suitable location for small devices to be placed in them — each lesion must be at least 1.5 cm across, as confirmed by a dermatologist.
• People who have waited long enough after previous treatments before joining the trial — specific waiting periods apply depending on the type of treatment previously received (confirm exact waiting times with the trial site), and no systemic (whole-body) therapy may be ongoing at the time the devices are placed.
• People aged 18 or older.
• People who are reasonably well and able to carry out daily activities, as measured by a standard health scoring scale (confirm with trial site).
• People whose recent blood test results (taken within 28 days before the procedure) show that their bone marrow is producing enough blood cells — specifically, a minimum level of infection-fighting cells and platelets.
• People who have been assessed by a dermatologist or cancer specialist, who will determine the most appropriate treatment plan based on their medical history and how far the disease has spread.
• People who their treating skin cancer specialist considers medically stable enough to safely undergo a minor procedure where a device is inserted through the skin.
• People who are able to understand and are willing to sign a written consent form agreeing to take part in the trial.
• People who are willing to have their genetic material analysed for research purposes, including having de-identified genetic data stored in approved government health research databases.
• People who are considered capable of following care instructions at home for the small devices, which will have a thin wire protruding through the skin while in place.

Who may not be able to join:

• People who have a positive pregnancy test at the screening visit.
• People who have a bleeding or blood-clotting disorder that cannot be corrected and that is known to increase the risk of surgical or biopsy procedures.
• People who have a history of allergic reactions to substances that are chemically or biologically similar to the agents used in this trial.
• People who have an uncontrolled ongoing illness — such as an active infection, heart failure, unstable chest pain, irregular heart rhythms, or a mental health or personal situation that would make it difficult to follow the trial's requirements.
• People who are receiving standard whole-body (systemic) cancer treatment as part of the trial and who would need to start a new skin-directed treatment (such as steroid creams, radiation, or light therapy) at the same time as the first systemic therapy given after the devices are placed and removed. (Skin-directed therapies may be considered later if the disease worsens and treatment needs to change — confirm with trial site.)
• People whose disease is progressing so rapidly that they need to start whole-body (systemic) treatment immediately and cannot wait out the required treatment washout period.

Important: Always verify eligibility with the trial site directly before applying.